Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

154.42 -0.98 (-0.63%)
Official Closing Price Updated: 7:00 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
80 81 Next >
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
A weekly look at top trending tickers seeing increased attention from Benzinga users. 
Via Benzinga
7 Tech Stocks to Light Up Your Portfolio This Holiday Season
Are you looking for the best tech stocks this holiday season? Here are seven stocks to light up your portfolio this holiday season. 
Via InvestorPlace
Investing in the Aging Population: 3 Healthcare Stocks to Watch
America is becoming a much older country on average. These three healthcare stocks are ideally positioned for this demographic shift. 
Via InvestorPlace
Vanda Pharmaceuticals Acquires Rights To Multiple Sclerosis Drug From Johnson & Johnson's Company
Vanda Pharmaceuticals Inc (NASDAQ: VNDA) has acquired U.S. 
Via Benzinga
(JNJ) - Analyzing Johnson & Johnson's Short Interest
Via Benzinga
JNJ CEO Signals No Rush Into Weight-Loss Drug Realm, Emphasizes Different Priorities
Johnson & Johnson (NYSE: JNJ) has no immediate plans to venture into weight-loss drugs due to the existing competition saturation, as Chief Executive Officer  
Via Benzinga
Elliott Wave Technical Analysis: Johnson & Johnson
Looking for longs into wave (v). 
Via Talk Markets
Bargain Buys: 7 Stocks Lagging the S&P 500 With Big Potential
While it might be tempting to jump onboard the top winners in the S&P 500, these bargain stocks might offer superior upside. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Johnson & Johnson Settles Multiple Lawsuits Over Talc Cancer Claims, Eyes Prepackaged Bankruptcy
Johnson & Johnson's (NYSE: JNJ) worldwide vice president for litigation, Erik Haas, disclosed recent settlements with several law firms regarding claims linking J&J talc  
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Is Buffett Turning Bearish? 7 Stocks Warren Completely Dumped in Q3
Warren Buffett stocks are typically bought to be held for a long time but sometimes even he finds it necessary to sell. 
Via InvestorPlace
Johnson & Johnson's Strategic Forecast: Targets 5%-6% Operational Sales Growth For FY24
Johnson & Johnson (NYSE: JNJ) expects operational sales growth in the  
Via Benzinga
Unleashing Growth Potential: Johnson &amp; Johnson Surpasses Expectations with Strong Performance and Increasing Profits
Via Benzinga
Nasdaq 100 Forecast: Stocks Slip For A Second Day With Jobs Data In Focus
Stocks are heading for a second day of losses as investors look ahead to data releases ahead of Friday's key non-farm payroll and next week's FOMC meeting. 
Via Talk Markets
The 7 Best Ways to Invest $1,000 in the Stock Market Now
Take a look at the seven best ways to invest $1,000 in the stock market and build a portfolio that generates passive income and gains. 
Via InvestorPlace
Top Contenders Emerge in Johnson & Johnson's Race for New CEO, Plans Under Spotlight After Unexpected Departure
The race for Johnson & Johnson's (NYSE: JNJ) top executive position has intensified following the unexpected exit of Ashley McEvoy, the former head of the company's medical device unit, potentially... 
Via Benzinga
Supreme Court Decision Looms Over Purdue Pharma's $6B Opioid Settlement And Sackler Family Immunity
The fate of a $6 billion bankruptcy settlement involving Purdue Pharma, the maker of the powerful and addictive pain medication OxyContin, hangs in th 
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
Warren Buffett Just Closed His Position in This Dividend Giant. Should You?
J&J has a long track record of dividend growth -- something Buffett generally appreciates. 
Via The Motley Fool
Barron's Weekend Stock Picks: Uber Joins The S&P 500, Schwab Rebounds And What's Next for Johnson & Johnson?
Benzinga reviews this weekend's top stories covered by Barron's. Here are the articles investors need to read. 
Via Benzinga
Topics Stocks
Exposures US Equities
Johnson & Johnson Gets Analyst Upgrade Noting Bullish Pharma & MedTech Projections
UBS has upgraded Johnson & Johnson (NYSE: JNJ), citing a bullish view of the company's pharmaceutical business and expectations for MedTech growth that align with the market, which is... 
Via Benzinga
Texas Attorney General Alleges Pfizer Misled Public on COVID-19 Vaccine Efficacy
Texas Attorney General Ken Paxton has filed a lawsuit against Pfizer Inc (NYSE: PFE), alleging the pharmaceutical giant misrepresented the efficacy of its widely- 
Via Benzinga
Topics Lawsuit
Exposures COVID-19 Financial Legal
Investors Should Not Pay More Than A 15 P/E Ratio When Buying A Stock
A look at how the P/E ratio can help determine if a stock is trading at a fair valuation or not, and whether it is a good investment. 
Via Talk Markets
Wealth From Wellness: 7 Healthcare Stocks to Inoculate Your Portfolio
Faced with a possible negative outcome in the market, these top healthcare stocks should offer the confidence you need. 
Via InvestorPlace
Warren Buffett Reduced This Long-Time Berkshire Hathaway Holding by 67%. Should Investors Follow His Lead?
Berkshire Hathaway trimmed several longtime holdings in the third quarter, including this stock it has held since 2001. 
Via The Motley Fool
Texas Sues Pfizer For "Misrepresenting COVID-19 Vaccine Efficacy" And "Conspiring To Censor Public Discourse"
The Texas attorney general is suing pharmaceutical giant Pfizer for misrepresenting the effectiveness of the company's Covid-19 
Via Talk Markets
Topics Lawsuit
Exposures COVID-19 Financial Legal
7 Blue-Chip Stocks to Buy for 2024, According to AI
Technical indicators can predict stock prices when paired with fundamental analysis. Here's MarketMasterAI's latest blue chip stock picks. 
Via InvestorPlace
Income Kings: 7 Blue-Chip Dividend Stocks for Reliable Returns
Are you looking for income kings with reliable returns? Here are seven blue-chip dividend stocks for reliable returns. 
Via InvestorPlace
Fresh on the Market: 3 Top Picks From the Renaissance IPO ETF
There have not been many successful IPOs in 2023, so finding stock picks from the Renaissance IPO ETF won’t be easy. 
Via InvestorPlace
Topics ETFs Initial Public Offering
Exposures Securities Market
Eyes On Novartis, Gilead, Bristol Myers As FDA Weighs Risks Vs. Benefits Of Approved CAR T-Cell Therapies
Tuesday, the FDA said it received reports of patients developing T-cell malig 
Via Benzinga
Exposures Product Safety
The 7 Biggest Dividend Stocks in Warren Buffett’s Portfolio
Are you curious about those Warren Buffet dividend stocks he owns in his portfolio? This article has you covered on the most important names. 
Via InvestorPlace
2 Unstoppable Dividend Stocks Trading Near 52-Week Lows to Buy Now
With clear advantages over the competition, these divided payers could deliver market-beating gains to patient investors. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
80 81 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.